CROMSOURCE is delivering several modules of a training course on clinical research best practice organized by the SIFC (Italian Cystic Fibrosis Society).
CROMSOURCE, an international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, is delivering several modules of a training course on clinical research best practice organized by the SIFC (Italian Cystic Fibrosis Society). The course commenced in December 2014 and will complete in February 2015.
Effective development of therapies in rare diseases such as cystic fibrosis relies on the involvement of physicians working in specialized clinics. These clinicians are then able to offer participation in such research projects to patients under their care. By offering training in clinical research best practice, SIFC hopes that physicians and their teams may be able to engage even more in future clinical research programs and offer participation to more patients with cystic fibrosis. During the course, CROMSOURCE personnel are training physicians and their teams on topics including typical aspects of a clinical research study protocol, the responsibilities of the physician and clinical staff who are involved in clinical research and the regulatory application and approval process for clinical research.
Read the full release here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.